Genotypic infection endpoint analysis to understand efficacy and escape potential of the malaria monoclonal antibody CIS43LS
- 1Department of Immunology and Infectious Diseases, Harvard TH Chan School of Public Health; Boston, MA, USA
Abstract
Early-phase trials of candidate malaria interventions in endemic areas often use "time-to-first" infection as a primary efficacy endpoint. This approach does not assess infection risk after the initial infection, and its censoring of trial participants after their first infection can introduce bias by removing more high-risk participants from control than treatment arms over time. Efficacy estimate precision may also decline as risk set size decreases. Here we assessed the utility of genotyping all infections in an intervention trial to determine the total infection incidence in each participant for the full follow-up period. Specifically, we genotyped all Plasmodium falciparum infections detected in a previously-reported phase 2 trial of the antimalarial monoclonal antibody CIS43LS in 330 Malian adults. We determined the molecular force of infection (molFOI; rate of new P. falciparum strains) for each participant, expressing efficacy as the percent molFOI reduction in CIS43LS versus placebo arms (EffmolFOI). Six-month EffmolFOI was 86.5% (95% CI: 80.1-90.8) and 70.7% (61.0-78.0) for the 40 mg/kg and 10 mg/kg doses, respectively. These estimates are similar to those from time-to-first infection analysis, but more precise when analyzing efficacy by trial-month and when stratifying by P. falciparum infection-status at enrollment. Participants infected at enrollment had lower EffmolFOI and acquired infections earlier in the trial, creating systematic differences in risk composition between arms over time. Genotyping showed no evidence for escape-polymorphisms in the CIS43LS epitope. These results demonstrate how genotypic endpoints can provide a more comprehensive understanding of candidate malaria interventions.
Related
- Targeting Integrins in Triple Negative Breast Cancer: Therapeutic Potential of Monoclonal Antibodies, PARP Inhibitors, Synthetic Peptides, and Aptamers
- A Monoclonal Antibody Targeting mGluR2 Inhibits H9 Subtype Influenza A Virus Infection In Vitro.
- Decoding Humoral Immunity During Acute MPXV Infection via Comprehensive Serological Analysis and Antigen-agnostic Monoclonal Antibody Profiling
- Differential Genotypic Effects of HSV-1 Infection on Cognitive Function and Pathology in the 5xFAD Mouse Model
- Optimization of a Human Anti-polio Monoclonal Antibody as a Potential Therapeutic Modality
BibTeX
@misc{schwabl2026genotypic,
title = {{Genotypic infection endpoint analysis to understand efficacy and escape potential of the malaria monoclonal antibody CIS43LS}},
author = {P. Schwabl and A. Niangaly and W. Nickols and V. Callier and A. Mateja and K. Kayentao and A. Ongoiba and J. Skinner and A. C. Preston and S. Doumbo and D. Doumtabe and J. E. Amaya-Romero and K. K. Kelley and S. Li and M. Laws and M. E. Peterson and T. M. Tran and S. C. Murphy and B. Traore and R. A. Seder and P. D. Crompton and G. E. Potter and D. E. Neafsey},
howpublished = {medRxiv},
year = {2026},
month = nov,
doi = {10.64898/2026.11.04.26367264},
url = {https://www.medrxiv.org/content/10.64898/2026.11.04.26367264v1},
note = {CC BY-NC},
}
RIS
TY - UNPB
TI - Genotypic infection endpoint analysis to understand efficacy and escape potential of the malaria monoclonal antibody CIS43LS
AU - P. Schwabl
AU - A. Niangaly
AU - W. Nickols
AU - V. Callier
AU - A. Mateja
AU - K. Kayentao
AU - A. Ongoiba
AU - J. Skinner
AU - A. C. Preston
AU - S. Doumbo
AU - D. Doumtabe
AU - J. E. Amaya-Romero
AU - K. K. Kelley
AU - S. Li
AU - M. Laws
AU - M. E. Peterson
AU - T. M. Tran
AU - S. C. Murphy
AU - B. Traore
AU - R. A. Seder
AU - P. D. Crompton
AU - G. E. Potter
AU - D. E. Neafsey
PY - 2026
DA - 2026/11/04
PB - medRxiv
DO - 10.64898/2026.11.04.26367264
UR - https://www.medrxiv.org/content/10.64898/2026.11.04.26367264v1
AB - Early-phase trials of candidate malaria interventions in endemic areas often use "time-to-first" infection as a primary efficacy endpoint. This approach does not assess infection risk after the initial infection, and its censoring of trial participants after their first infection can introduce bias by removing more high-risk participants from control than treatment arms over time. Efficacy estimate precision may also decline as risk set size decreases. Here we assessed the utility of genotyping all infections in an intervention trial to determine the total infection incidence in each participant for the full follow-up period. Specifically, we genotyped all Plasmodium falciparum infections detected in a previously-reported phase 2 trial of the antimalarial monoclonal antibody CIS43LS in 330 Malian adults. We determined the molecular force of infection (molFOI; rate of new P. falciparum strains) for each participant, expressing efficacy as the percent molFOI reduction in CIS43LS versus placebo arms (EffmolFOI). Six-month EffmolFOI was 86.5% (95% CI: 80.1-90.8) and 70.7% (61.0-78.0) for the 40 mg/kg and 10 mg/kg doses, respectively. These estimates are similar to those from time-to-first infection analysis, but more precise when analyzing efficacy by trial-month and when stratifying by P. falciparum infection-status at enrollment. Participants infected at enrollment had lower EffmolFOI and acquired infections earlier in the trial, creating systematic differences in risk composition between arms over time. Genotyping showed no evidence for escape-polymorphisms in the CIS43LS epitope. These results demonstrate how genotypic endpoints can provide a more comprehensive understanding of candidate malaria interventions.
ER -